Huonslab strengthens HyDIFFUZE IP with completion of US, EU examination request under PCT application

Q: How long will it take to read this news story?

The story "Huonslab strengthens HyDIFFUZE IP with completion of US, EU examination request under PCT application" has 230 words across 12 sentences, which will take approximately 1 - 2 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Huonslab strengthens HyDIFFUZE IP with completion of US, EU examination request under PCT application" was covered 1 weeks ago by Korea Economic Daily, a news publisher based in South Korea.

Q: How trustworthy is 'Korea Economic Daily' news outlet?

Korea Economic Daily is a fully independent (privately-owned) news outlet established in 1964 that covers mostly economy news. The outlet is headquartered in South Korea and publishes an average of 2 news stories per day. It's most recent story was published 10 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #23544865</li><li>URL: https://beamstart.com/news/huonslab-strengthens-hydiffuze-ip-with-17313899184</li></ul>

Korea Economic Daily Logo Korea Economic Daily 1w ago

Huonslab strengthens HyDIFFUZE IP with completion of US, EU examination request under PCT application - Korea Economic Daily

Quick Summary:

The production method filed by Huonslab produces high-purity recombinant human hyaluronidase with high yield by expressing it in its complete form and optimizing the purification process, completing the international patent application following domestic registration.“Filing of PCT application of HyDIFFUZE™(rHuPH20) Process Patent is pivotal to Huonslab IP asset management, enhancing our robust patent estate and endeavor to achieve universal large volume antibody SC delivery based on HyDIFFUZE(rHuPH20),” said Dr.

South Korea’s Huonslab Co., a subsidiary of Huons Global Co.and a global leader in recombinant human hyaluronidase-based biologics Sub-Q delivery, announced on Monday that it has successfully completed patent filling and examination requests for its recombinant human hyaluronidase in both US and EU, based on its PCT application.

Huonslab is also developing HLB3-002, a stand-alone rHuPH20 drug product under the brand name of Hydizyme™ in the registration study(N=245) in Korea, anticipating MFDS BLA in 2026.